
|Videos|June 30, 2021
Medical World News® Deep Dive: Expert Talks FDA Approval of Amivantamab to Treat NSCLC With EGFR Exon 20 Insertion Mutations
Author(s)Matthew Fowler
Joshua Sabari, MD, discussed the approval of amivantiamab as therapy for patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations.
Advertisement
In this episode of Deep Dive from the
Sabari detailed the challenges of treating tumors with this mutation and compared amivantamab with the other systemic therapy options in this setting. He also discusses what the future might have in store for amivantamab in this specific disease.
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
Olomorasib Earns FDA Breakthrough Therapy in KRAS G12C+ Pancreatic Cancer
2
Epcoritamab Combo Shows Sustained Remissions in Follicular Lymphoma
3
What Makes an Optimal CAR T-Cell Therapy Candidate in Multiple Myeloma
4
FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma
5





















































